Skip to main content
Erschienen in:

01.05.2005 | Leitthema

Immuntherapie gastrointestinaler Tumoren

verfasst von: PD Dr. D. Meyer, B. Illert, W. Timmermann, A. Thiede, A. M. Waaga-Gasser

Erschienen in: Die Onkologie | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die kritische Auswertung der innerhalb der letzten Jahre erarbeiteten Daten zur Immuntherapie des Magen- und des kolorektalen Karzinoms eröffnet Möglichkeiten, das Wachstum und die metastatische Dissemination dieser Tumoren immunologisch zu modifizieren. Die molekulare Charakterisierung tumorassoziierter Antigene (TAA) schreitet schnell voran. Damit erweitert sich das Spektrum potenzieller Ziele einer Immuntherapie und schafft die Möglichkeit, moderne Techniken zum Monitoring der gegen sie gerichteten Antikörper und T-Zell-Antworten anzuwenden. Somit sind die Untersuchungen zur Immuntherapie auf diesem Gebiet als Erfolg zu werten. Dennoch sind die klinischen Fortschritte sowohl für das Magen- wie auch für das kolorektale Karzinom begrenzt. Erfahrungen aus der Melanomvakzinierung, die Entwicklung neuer Generationen wirkungsvollerer Antitumorvakzine, neuer Adjuvantien (dendritische Zellen: DC, Hitzeschockprotein: HSP) und chemisch modifizierter antigener Peptide weisen aber den Weg zu einer verbesserten Immuntherapie durch Verstärkung der tumoreigenen Immunogenität. Eine Chance könnte hierbei insbesondere in der T-Zell-basierten Immuntherapie liegen.
Literatur
1.
Zurück zum Zitat Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio, F, Piperno A, Aldeghi R, Fossati D et al. (1993) Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer 67:1404–1407 Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio, F, Piperno A, Aldeghi R, Fossati D et al. (1993) Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer 67:1404–1407
2.
Zurück zum Zitat Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G, Uggeri F, Conti M (2004) Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients. Hepatogastroenterology 51:1872–1876 Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G, Uggeri F, Conti M (2004) Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients. Hepatogastroenterology 51:1872–1876
3.
Zurück zum Zitat Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, Uggeri F (2004) Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 88:240–247 Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, Uggeri F (2004) Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 88:240–247
4.
Zurück zum Zitat Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y (2002) Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8:1767–1771 Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y (2002) Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8:1767–1771
5.
Zurück zum Zitat Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M (2001) Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85:713–720 Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M (2001) Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85:713–720
6.
Zurück zum Zitat Sato Y, Shomura H, Maeda Y et al. (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94:802–808 Sato Y, Shomura H, Maeda Y et al. (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94:802–808
7.
Zurück zum Zitat Sasada T, Takedatsu H, Azuma K, Koga M, Maeda Y, Shichijo S, Shoumura H, Hirai T, Takabayashi A, Itoh K (2004) Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 64:2882–2888 Sasada T, Takedatsu H, Azuma K, Koga M, Maeda Y, Shichijo S, Shoumura H, Hirai T, Takabayashi A, Itoh K (2004) Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 64:2882–2888
8.
Zurück zum Zitat Shibata M, Nezu T, Fujisaki S, Andou K, Tomita R, Fukuzawa M (2002) Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience. Dig Surg 19:255–260 Shibata M, Nezu T, Fujisaki S, Andou K, Tomita R, Fukuzawa M (2002) Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience. Dig Surg 19:255–260
9.
Zurück zum Zitat Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, Okamura S, Sato K, Orita K (1994) Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer 74:3097–3103 Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, Okamura S, Sato K, Orita K (1994) Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer 74:3097–3103
10.
Zurück zum Zitat Gochi A, Orita K, Fuchimoto S, Tanaka N, Ogawa N (2001) The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84:443–451 Gochi A, Orita K, Fuchimoto S, Tanaka N, Ogawa N (2001) The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84:443–451
11.
Zurück zum Zitat Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS (1998) OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer 83:2054–2059 Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS (1998) OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer 83:2054–2059
12.
Zurück zum Zitat Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y, Ohashi Y (2002) Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 25:405–412 Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y, Ohashi Y (2002) Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 25:405–412
13.
Zurück zum Zitat Watson SA, Michaeli D, Grimes S, Morris TM, Varro A, Clarke PA, Smith AM, Justin TA, Hardcastle JD (1999) A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice. Int J Cancer 81:248–254 Watson SA, Michaeli D, Grimes S, Morris TM, Varro A, Clarke PA, Smith AM, Justin TA, Hardcastle JD (1999) A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice. Int J Cancer 81:248–254
14.
Zurück zum Zitat Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D (2004) A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 30:536–543 Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D (2004) A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 30:536–543
15.
Zurück zum Zitat Houshmand P, Zlotnik A (2003) Targeting tumor cells. Curr Opin Cell Biol 15:640–644 Houshmand P, Zlotnik A (2003) Targeting tumor cells. Curr Opin Cell Biol 15:640–644
16.
Zurück zum Zitat Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D (2000) A multi-institutional phase II study of BMS-182248–01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6:78–81 Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D (2000) A multi-institutional phase II study of BMS-182248–01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6:78–81
17.
Zurück zum Zitat Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15:517–525 Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15:517–525
18.
Zurück zum Zitat Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, Matsuo K, Awane M, Shimahara Y, Takabayashi A, Yamaoka Y, Satoh S (2004) Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 95:328–333 Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, Matsuo K, Awane M, Shimahara Y, Takabayashi A, Yamaoka Y, Satoh S (2004) Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 95:328–333
19.
Zurück zum Zitat Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813–5817 Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813–5817
20.
Zurück zum Zitat Illert B, Fein M, Otto C, Cording F, Stehle D, Thiede A, Timmermann W (2005) Disseminated tumor cells in the blood of patients with gastric cancer are an independent marker of poor prognosis. Scand J Gastroenterol (im Druck) Illert B, Fein M, Otto C, Cording F, Stehle D, Thiede A, Timmermann W (2005) Disseminated tumor cells in the blood of patients with gastric cancer are an independent marker of poor prognosis. Scand J Gastroenterol (im Druck)
21.
Zurück zum Zitat Illert B, Otto C, Vollmers H, Hensel F, Thiede A, Timmermann W (2005) Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol Rep (im Druck) Illert B, Otto C, Vollmers H, Hensel F, Thiede A, Timmermann W (2005) Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol Rep (im Druck)
22.
Zurück zum Zitat Timmermann W, Illert B, Reindl L, Ruckle-Lanz H, Wilhelm M, Hensel F, Vollmers H, Muller-Hermelink H, Coquoz D, Thiede A (2004) Prognostic effect of CD55-SC-1 in gastric carcinoma (GC) and survival after treatment with the monoclonal antibody SC-1. American Society of Clinical Oncology. Annual Proceedings of the 40th ASCO Meeting 23, Abstract 4067 Timmermann W, Illert B, Reindl L, Ruckle-Lanz H, Wilhelm M, Hensel F, Vollmers H, Muller-Hermelink H, Coquoz D, Thiede A (2004) Prognostic effect of CD55-SC-1 in gastric carcinoma (GC) and survival after treatment with the monoclonal antibody SC-1. American Society of Clinical Oncology. Annual Proceedings of the 40th ASCO Meeting 23, Abstract 4067
23.
Zurück zum Zitat Schwartzberg LS (2001) Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 40:17–24 Schwartzberg LS (2001) Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 40:17–24
24.
Zurück zum Zitat Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45:5910–5913 Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45:5910–5913
25.
Zurück zum Zitat Masucci G, Ragnhammar P, Frodin JE, Hjelm AL, Wersall P, Fagerberg J, Osterborg A, Mellstedt H (1991) Chemotherapy and immunotherapy of colorectal cancer. Med Oncol Tumor Pharmacother 8:207–220 Masucci G, Ragnhammar P, Frodin JE, Hjelm AL, Wersall P, Fagerberg J, Osterborg A, Mellstedt H (1991) Chemotherapy and immunotherapy of colorectal cancer. Med Oncol Tumor Pharmacother 8:207–220
26.
Zurück zum Zitat Hjelm Skog A, Ragnhammar P, Fagerberg J et al. (1999) Clinical effects of monoclonal antibody 17–1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol Immunother 48:463–470 Hjelm Skog A, Ragnhammar P, Fagerberg J et al. (1999) Clinical effects of monoclonal antibody 17–1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol Immunother 48:463–470
27.
Zurück zum Zitat Riethmuller G, Holz E, Schlimok G et al. (1998) Monoclonal antibody therapy for resected Dukes‘ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794 Riethmuller G, Holz E, Schlimok G et al. (1998) Monoclonal antibody therapy for resected Dukes‘ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794
28.
Zurück zum Zitat Punt CJ, Nagy A, Douillard JY et al. (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360:671–677 Punt CJ, Nagy A, Douillard JY et al. (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360:671–677
29.
Zurück zum Zitat Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021–7025 Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021–7025
30.
Zurück zum Zitat Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR, de Leij L (1998) Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 76:232–239 Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR, de Leij L (1998) Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 76:232–239
31.
Zurück zum Zitat Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, Wolf J, Diehl V, Cochet O, Winter G, Bohlen H (1999) Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 59:2909–2916 Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, Wolf J, Diehl V, Cochet O, Winter G, Bohlen H (1999) Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 59:2909–2916
32.
Zurück zum Zitat Spaulding DC, Spaulding BO (2002) Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 29:45–54 Spaulding DC, Spaulding BO (2002) Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 29:45–54
33.
Zurück zum Zitat Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346 Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346
34.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
35.
Zurück zum Zitat Ellis LM, Hoff PM (2004) Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 22 1177–1179 Ellis LM, Hoff PM (2004) Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 22 1177–1179
36.
Zurück zum Zitat Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208 Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208
37.
Zurück zum Zitat Lenz HJ, Mayer RJ, Gold PJ (2004) Activity of cetuximab in patients with colorectal cancer refrectory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 23:248 Lenz HJ, Mayer RJ, Gold PJ (2004) Activity of cetuximab in patients with colorectal cancer refrectory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 23:248
38.
Zurück zum Zitat Baselga J (2001) The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 37 [Suppl 4]:S16–22 Baselga J (2001) The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 37 [Suppl 4]:S16–22
39.
Zurück zum Zitat Herbst RS, Langer CJ (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27–36 Herbst RS, Langer CJ (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27–36
40.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342
41.
Zurück zum Zitat Foon KA, Yannelli J, Bhattacharya-Chatterjee M (1999) Colorectal cancer as a model for immunotherapy. Clin Cancer Res 5:225–236 Foon KA, Yannelli J, Bhattacharya-Chatterjee M (1999) Colorectal cancer as a model for immunotherapy. Clin Cancer Res 5:225–236
42.
Zurück zum Zitat Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW (1999) Strategies in the development of recombinant vaccines for colon cancer. Semin Oncol 26:672–682 Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW (1999) Strategies in the development of recombinant vaccines for colon cancer. Semin Oncol 26:672–682
43.
Zurück zum Zitat Bremers AJ, Parmiani G (2000) Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 34:1–25 Bremers AJ, Parmiani G (2000) Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 34:1–25
44.
Zurück zum Zitat Zeh HJ, Stavely-O’Carroll K, Choti MA (2001) Vaccines for colorectal cancer. Trends Mol Med 7:307–313 Zeh HJ, Stavely-O’Carroll K, Choti MA (2001) Vaccines for colorectal cancer. Trends Mol Med 7:307–313
45.
Zurück zum Zitat Sobol RE, Shawler DL, Carson C et al. (1999) Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res 5:2359–2365 Sobol RE, Shawler DL, Carson C et al. (1999) Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res 5:2359–2365
46.
Zurück zum Zitat Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS (1999) Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother 22:251–259 Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS (1999) Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immunother 22:251–259
47.
Zurück zum Zitat Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL (2001) CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 8:389–401 Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL (2001) CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 8:389–401
48.
Zurück zum Zitat Gray BN, Walker C, Andrewartha L, Freeman S, Bennett RC (1989) Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol 40:34–37 Gray BN, Walker C, Andrewartha L, Freeman S, Bennett RC (1989) Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol 40:34–37
49.
Zurück zum Zitat Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390–399 Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390–399
50.
Zurück zum Zitat Vermorken JB, Claessen AM, van Tinteren H et al. (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350 Vermorken JB, Claessen AM, van Tinteren H et al. (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350
51.
Zurück zum Zitat Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, Mansour E, Haller DG, Manola J, Hanna MG Jr (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18:148–157 Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, Mansour E, Haller DG, Manola J, Hanna MG Jr (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18:148–157
52.
Zurück zum Zitat Hanna MG Jr, Hoover HC, Jr, Vermorken JB, Harris JE, Pinedo HM (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19:2576–2582 Hanna MG Jr, Hoover HC, Jr, Vermorken JB, Harris JE, Pinedo HM (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19:2576–2582
53.
Zurück zum Zitat Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303–313 Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303–313
54.
Zurück zum Zitat Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G (2001) Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61 222–227 Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G (2001) Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61 222–227
55.
Zurück zum Zitat Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL (1998) Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8:657–665 Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL (1998) Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8:657–665
56.
Zurück zum Zitat Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11:263–270 Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11:263–270
57.
Zurück zum Zitat Parmiani G, Castelli C, Dalerba P, Rivoltini L (2001) T cell response to tumor antigens and its therapeutic use in cancer patients. Adv Exp Med Biol 495:403–410 Parmiani G, Castelli C, Dalerba P, Rivoltini L (2001) T cell response to tumor antigens and its therapeutic use in cancer patients. Adv Exp Med Biol 495:403–410
58.
Zurück zum Zitat Mazzaferro V, Coppa J, Carrabba MG et al. (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9:3235–3245 Mazzaferro V, Coppa J, Carrabba MG et al. (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9:3235–3245
59.
Zurück zum Zitat Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982–990 Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982–990
60.
Zurück zum Zitat McAneny D, Ryan CA, Beazley RM, Kaufman HL (1996) Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 3:495–500 McAneny D, Ryan CA, Beazley RM, Kaufman HL (1996) Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 3:495–500
61.
Zurück zum Zitat Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J (1999) Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332–337 Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J (1999) Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332–337
62.
Zurück zum Zitat Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964–3973 Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964–3973
63.
Zurück zum Zitat Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A., Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL (2000) Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49:504–514 Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A., Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL (2000) Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49:504–514
64.
Zurück zum Zitat von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM (2000) Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 6:2219–2228 von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM (2000) Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 6:2219–2228
65.
Zurück zum Zitat Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK (1999) A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331–1338 Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK (1999) A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331–1338
66.
Zurück zum Zitat Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809–8814 Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809–8814
67.
Zurück zum Zitat Staib L, Birebent B, Somasundaram R et al. (2001) Immunogenicity of recombinant GA733–2E antigen (CO17–1A, EGP, KS1–4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 92:79–87 Staib L, Birebent B, Somasundaram R et al. (2001) Immunogenicity of recombinant GA733–2E antigen (CO17–1A, EGP, KS1–4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 92:79–87
68.
Zurück zum Zitat Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT (1996) A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298–304 Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT (1996) A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298–304
69.
Zurück zum Zitat Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF (2001) Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother 24:172–183 Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF (2001) Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother 24:172–183
70.
Zurück zum Zitat Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182:137–151 Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182:137–151
71.
Zurück zum Zitat Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J (1999) A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22:155–165 Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J (1999) A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22:155–165
72.
Zurück zum Zitat Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997) Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72:784–790 Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997) Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72:784–790
73.
Zurück zum Zitat Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K (2001) Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 7:3950–3962 Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K (2001) Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 7:3950–3962
74.
Zurück zum Zitat Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277–2284 Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277–2284
75.
Zurück zum Zitat Van den Eynde BJ, Morel S (2001) Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 13:147–153 Van den Eynde BJ, Morel S (2001) Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 13:147–153
76.
Zurück zum Zitat Birebent B, Somasundaram R, Purev E et al. (2001) Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. Crit Rev Oncol Hematol 39:107–113 Birebent B, Somasundaram R, Purev E et al. (2001) Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. Crit Rev Oncol Hematol 39:107–113
77.
Zurück zum Zitat Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685–689 Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685–689
78.
Zurück zum Zitat Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113–1124 Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113–1124
79.
Zurück zum Zitat Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, Henne-Bruns D, Kremer B, Kalthoff H (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 57:3106–3110 Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, Henne-Bruns D, Kremer B, Kalthoff H (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 57:3106–3110
80.
Zurück zum Zitat Guadagni F, Kantor J, Aloe S et al. (2001) Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Cancer Res 61:2523–2532 Guadagni F, Kantor J, Aloe S et al. (2001) Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Cancer Res 61:2523–2532
81.
Zurück zum Zitat Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5:3999–4004 Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5:3999–4004
82.
Zurück zum Zitat Schirrmacher V (2001) T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 11:285–295 Schirrmacher V (2001) T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 11:285–295
83.
Zurück zum Zitat Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:452–458 Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:452–458
84.
Zurück zum Zitat Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353–362 Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353–362
85.
Zurück zum Zitat Gupta S, Seth SK, Udupa KN, Sen PC (1980) Delayed cutaneous hypersensitivity ad peripheral blood lymphocyte counts in gastrointestinal cancer. Ann Acad Med Singapore 9:71–76 Gupta S, Seth SK, Udupa KN, Sen PC (1980) Delayed cutaneous hypersensitivity ad peripheral blood lymphocyte counts in gastrointestinal cancer. Ann Acad Med Singapore 9:71–76
86.
Zurück zum Zitat Papatheodorou K, Triantafillidis JK, Kogevinas M, Manoussakis K, Nicolakis D, Merikas E (1994) Cutaneous delayed hypersensitivity in patients with colorectal cancer: application of multi-test. Ital J Gastroenterol 26:12–15 Papatheodorou K, Triantafillidis JK, Kogevinas M, Manoussakis K, Nicolakis D, Merikas E (1994) Cutaneous delayed hypersensitivity in patients with colorectal cancer: application of multi-test. Ital J Gastroenterol 26:12–15
87.
Zurück zum Zitat Huang A, Quinn H, Glover C, Henderson DC, Allen-Mersh TG (2002) The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation. Cancer Immunol Immunother 51:53–57 Huang A, Quinn H, Glover C, Henderson DC, Allen-Mersh TG (2002) The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation. Cancer Immunol Immunother 51:53–57
88.
Zurück zum Zitat Elsasser-Beile U, von Kleist S, Fischer R, Monting JS (1992) Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls. J Clin Lab Anal 6:311–314 Elsasser-Beile U, von Kleist S, Fischer R, Monting JS (1992) Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls. J Clin Lab Anal 6:311–314
89.
Zurück zum Zitat O’Hara RJ, Greenman J, Drew PJ, McDonald AW, Duthie GS, Lee PW, Monson JR (1998) Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer. Dis Colon Rectum 41:460–463 O’Hara RJ, Greenman J, Drew PJ, McDonald AW, Duthie GS, Lee PW, Monson JR (1998) Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer. Dis Colon Rectum 41:460–463
90.
Zurück zum Zitat Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82:1009–1012 Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82:1009–1012
91.
Zurück zum Zitat Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765–772 Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765–772
92.
Zurück zum Zitat Choi SH, Chung EJ, Whang DY, Lee SS, Jang YS, Kim CW (1998) Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer Immunol Immunother 45:299–305 Choi SH, Chung EJ, Whang DY, Lee SS, Jang YS, Kim CW (1998) Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer Immunol Immunother 45:299–305
93.
Zurück zum Zitat Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2:1263–1274 Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2:1263–1274
94.
Zurück zum Zitat O’Connell J, O’Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075–1082 O’Connell J, O’Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075–1082
95.
Zurück zum Zitat Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023–5027 Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023–5027
96.
Zurück zum Zitat Bandealy MT, Gonin R, Loehrer PJ, Monaco F, Einhorn LH (1998) Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. Clin Cancer Res 4:935–939 Bandealy MT, Gonin R, Loehrer PJ, Monaco F, Einhorn LH (1998) Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. Clin Cancer Res 4:935–939
97.
Zurück zum Zitat Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G (1998) Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220–1230 Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G (1998) Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220–1230
Metadaten
Titel
Immuntherapie gastrointestinaler Tumoren
verfasst von
PD Dr. D. Meyer
B. Illert
W. Timmermann
A. Thiede
A. M. Waaga-Gasser
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0866-9

Weitere Artikel der Ausgabe 5/2005

Der Onkologe 5/2005 Zur Ausgabe

Onkologie im Internet

Webadressen zur Immuntherapie

Weiterbildung · Zertifizierte Fortbildung

Nierenzellkarzinom

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Schon länger ist bekannt, dass die Aktivität des Immunsystems mit den Jahreszeiten variiert. Auch die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen, wie eine Studie bei fortgeschrittenem nichtkleinzelligem Lungenkarzinom zeigt.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.